Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Canagliflozin impurity 1 is a specific impurity associated with the SGLT2 inhibitor Canagliflozin, which targets sodium-glucose co-transporter 2 to facilitate glucose excretion. This compound is essential for understanding the metabolite profile and purity assessment of Canagliflozin in pharmaceutical formulations and research applications. Its characterization is crucial for ensuring the quality and efficacy of drug substances in regulatory compliance and safety evaluations. -
Drug Impurity
Tamsulosin impurity 10 is a known impurity associated with Tamsulosin, a selective alpha-1 adrenergic antagonist. It serves as an important reference standard for quality control and analytical studies in pharmaceutical research. Its characterization aids in understanding the purity and stability of Tamsulosin formulations, ensuring compliance with regulatory standards in drug development. -
Drug Impurity
Sitagliptin impurity 18 is a known impurity associated with the DPP-4 inhibitor Sitagliptin. This compound is critical for quality control and analytical research, providing insights into the purity and stability of Sitagliptin formulations. It is commonly used in pharmaceutical development and regulatory compliance studies to ensure that drug products meet necessary safety and efficacy standards. -
Drug Impurity
Estradiol Valerate impurity 4 is a known impurity associated with Estradiol Valerate, a hormone used in various therapeutic applications. Understanding this impurity is essential for ensuring the purity and safety of pharmaceutical formulations containing Estradiol Valerate. It serves as an important reference standard in drug development and quality control processes in the pharmaceutical industry. -
Drug Impurity
Rosuvastatin impurity 5 is a known impurity associated with the statin compound Rosuvastatin. This chemical is primarily utilized in the analytical evaluation of pharmaceutical formulations to ensure quality and compliance. Researchers employ Rosuvastatin impurity 5 in stability studies and impurity profiling, aiding in the development and regulatory assessment of therapeutic agents targeting cholesterol reduction. -
Drug Impurity
Ranitidine impurity 12 is a known impurity associated with the drug Ranitidine. It serves as a reference compound for the detection and quantification of impurities in pharmaceutical formulations. This compound is essential for quality control and compliance testing in drug development studies, particularly in the assessment of Ranitidine's purity and stability. Its analysis contributes to the overall understanding of the safety and efficacy of Ranitidine-containing products. -
Drug Impurity
Avatrombopag impurity 57 is a chemical impurity associated with Avatrombopag, a thrombopoietin receptor agonist. This impurity is critical for quality control and analytical studies in pharmaceutical research, ensuring the integrity and safety of Avatrombopag formulations. Its characterization supports the development and validation of analytical methods in the evaluation of drug purity and stability. -
Drug Impurity
Rivaroxaban impurity 22 is a chemical impurity associated with the anticoagulant Rivaroxaban. This compound is important for quality control and analytical studies in pharmaceutical research, particularly in assessing the purity and stability of Rivaroxaban formulations. Its characterization can aid in understanding the metabolic pathways and potential side effects of Rivaroxaban, contributing to the advancement of drug safety and efficacy studies. -
Drug Impurity
Azilsartan impurity 9, also known as Azilsartan impurity H, is a chemical reagent classified as a drug impurity of Azilsartan. It is utilized primarily for quality control and analytical applications in pharmaceutical research, particularly in the analysis of drug formulations. Understanding and quantifying impurities like Azilsartan impurity 9 is essential for ensuring the safety and efficacy of pharmaceutical products. -
Drug Impurity
Roflumilast impurity 2 is a chemical byproduct associated with Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor. This impurity is significant for analytical and quality control studies in pharmaceutical research, ensuring the integrity and safety of formulations containing Roflumilast. Its identification and quantification are essential for regulatory compliance and the development of therapeutic applications. -
Drug Impurity
Tacrolimus impurity 5 is a known impurity of the immunosuppressant drug Tacrolimus, which targets the protein phosphatase Calcineurin. This reagent can be utilized in analytical chemistry for the characterization and quantification of Tacrolimus formulations. Its study is important for ensuring the quality and safety of pharmaceutical products involving Tacrolimus. -
Drug Impurity
Canagliflozin tetraacetate is a chemical impurity associated with the SGLT2 inhibitor Canagliflozin. It is primarily used as a reference standard for analytical and quality control purposes in pharmaceutical research. The identification and quantification of this impurity are important for evaluating the purity and safety profiles of Canagliflozin in drug development and formulation studies. -
Drug Impurity
Tenofovir isoproxil monoester is a drug impurity of interest primarily in the synthesis and quality control of antiviral medications. This compound serves as a critical marker in pharmacokinetic studies and can be utilized in analytical applications to ensure the integrity and safety of Tenofovir formulations. It plays a significant role in the assessment of drug purity and regulatory compliance within pharmaceutical research. -
Drug Impurity
4-(2-(tert-Butylamino)ethyl)-2-methylphenol, also known as Salbutamol Impurity, is a known impurity of the bronchodilator Salbutamol. This compound serves as a critical reference standard for the identification and quantification of impurities in pharmaceutical formulations. Its detection is essential in ensuring the purity and quality of Salbutamol during analytical assessments in drug development and manufacturing processes. -
Drug Impurity
Levofloxacin impurity 11 is a synthetic impurity associated with Levofloxacin. This compound serves as an important analytical standard for quality control in pharmaceutical research and development. Its characterization is critical for ensuring the purity and efficacy of Levofloxacin formulations, contributing to the overall safety profile of the drug in clinical applications. -
Drug Impurity
Salbutamol impurity 8 (N-Benzyl albuterol) is a chemical impurity associated with the pharmaceutical agent Salbutamol. It serves as a reference standard for the identification and quantification of impurities during quality control processes in drug development and manufacturing. This compound is essential for ensuring the safety and efficacy of Salbutamol formulations in respiratory therapeutic applications. -
Drug Impurity
Clindamycin palmitate impurity 7, also known as Clindamycin stearate, is a characterized drug impurity associated with clindamycin formulations. It is primarily relevant in the assessment of drug purity and quality control processes. This compound is utilized in pharmaceutical research and development to ensure the integrity and safety of antibiotic formulations, providing critical insights into impurity profiles and their potential impact on therapeutic efficacy. -
Drug Impurity
Budesonide impurity 85, also known as 21-Dehydro budesonide, is a drug impurity associated with the corticosteroid Budesonide. This compound serves as an important analytical standard for quality control in pharmaceutical formulations. Its examination is critical for ensuring the purity of Budesonide products and for assessing their safety and efficacy in clinical applications. -
Drug Impurity
Apixaban Impurity 19 is a chemical impurity associated with the anticoagulant drug Apixaban. This compound is critical for quality control and analytical studies in pharmaceutical research, enabling researchers to assess the purity and safety of Apixaban formulations. It serves as a reference standard for method validation and impurity profiling in drug development and compliance testing. -
Drug Impurity
Alfacalciferol impurity 1 is a characterized impurity associated with the active form of vitamin D, Alfacalciferol. This compound is relevant in the assessment of drug purity and quality control in pharmaceutical formulations that contain Alfacalciferol. Its presence can be significant in understanding the pharmacokinetics and metabolic pathways of vitamin D compounds in biological research. -
Drug Impurity
Betamethasone valerate impurity 2 is a drug impurity associated with Betamethasone valerate. It serves as an important marker for quality control and characterization in pharmaceutical formulations. Its identification and analysis are crucial for ensuring the purity and safety of corticosteroid products used in various therapeutic applications. -
Drug Impurity
Ketoprofen Impurity 1 is a known impurity of the non-steroidal anti-inflammatory drug (NSAID) Ketoprofen. It serves as a valuable standard for quality control and analytical applications in pharmaceutical research. Studying this impurity aids in understanding the metabolic profile and potential degradation pathways of Ketoprofen, ensuring the integrity of formulations containing this compound. -
Drug Impurity
Levetiracetam impurity 3 is a chemical impurity associated with the anticonvulsant drug Levetiracetam. This impurity may be utilized in analytical chemistry studies to assess the purity and stability of Levetiracetam formulations. It is valuable for researchers analyzing drug composition and conducting quality control assessments in pharmaceutical development. -
Drug Impurity
Alfuzosin EP impurity 1 hydrochloride, also known as 2,3,4,5-Tetradehydro alfuzosin hydrochloride, is a recognized impurity of Alfuzosin hydrochloride. This compound is essential for evaluating the purity and stability of alfuzosin formulations in pharmaceutical development. Researchers may utilize this impurity in studies assessing drug quality, pharmacokinetics, and mechanism of action related to alpha-1 adrenergic receptor antagonism. -
Drug Impurity
Imatinib impurity 21 is a known impurity related to the tyrosine kinase inhibitor Imatinib. This compound serves as an important reference standard in analytical chemistry to evaluate the purity and stability of Imatinib formulations. Its analysis is critical for ensuring compliance with regulatory standards in the pharmaceutical industry and for assessing potential biological impacts in drug safety studies. -
Drug Impurity
Azilsartan impurity 31 is a known impurity associated with Azilsartan, an angiotensin II receptor antagonist. This compound is primarily used in pharmaceutical research to ensure the quality and purity of Azilsartan formulations. Its characterization is crucial for regulatory compliance and assessment of potential effects in drug safety evaluations. -
Drug Impurity
Losartan impurity 19, also known as N1-Losartanyl-losartan, is a specific impurity associated with the angiotensin II receptor antagonist Losartan. This compound is used primarily for analytical purposes in quality control and characterization of Losartan formulations. It aids in the assessment of the purity and stability of Losartan products, ensuring compliance with regulatory standards in pharmaceutical research and development. -
Drug Impurity
Levothyroxine impurity 14, also known as 3-Chloro-3’,5,5’-triiodo-L-thyronine, is classified as a drug impurity. This compound may arise during the synthesis or degradation of levothyroxine and is essential for assessing the purity and quality of pharmaceutical formulations. Its identification and quantification are critical in ensuring product safety and efficacy in thyroid hormone therapies. -
Drug Impurity
Crizotinib impurity 1 is a noted impurity associated with the targeted therapy Crizotinib, primarily acting on the anaplastic lymphoma kinase (ALK) and c-MET pathways. This compound is essential for assessing the purity of Crizotinib formulations in pharmaceutical development and quality control. Its analysis is crucial for ensuring compliance with regulatory standards related to drug safety and efficacy. -
Drug Impurity
Levofloxacin impurity 8 is a known impurity of the antibiotic Levofloxacin. It serves as a critical reference standard for assessing the purity and quality of pharmaceutical formulations containing Levofloxacin. This compound is essential for analytical studies and regulatory compliance, particularly in the development and quality control of antibacterial drugs. -
Drug Impurity
Olmesartan Impurity 5 is a chemical byproduct associated with the synthesis of Olmesartan, an antihypertensive agent. This impurity serves as a reference standard for quality control and regulatory compliance in pharmaceutical research. It is critical for analytical method development and validation, ensuring the purity and safety of Olmesartan in drug formulations. -
Drug Impurity
Donepezil impurity 13 is a chemical impurity associated with Donepezil, a reversible inhibitor of acetylcholinesterase. It serves as an important reference standard in analytical chemistry for the assessment of pharmaceutical purity. This compound is utilized in the quality control and stability testing of Donepezil formulations, ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
Grazoprevir impurity 1 is a structural variant of Grazoprevir, a direct-acting antiviral agent targeting the hepatitis C virus (HCV) protease. This impurity is utilized in analytical chemistry for impurity profiling and quality control in pharmaceutical development. Its characterization is essential for ensuring the purity and safety of Grazoprevir formulations in research and clinical applications. -
Drug Impurity
Abacavir impurity 6 is a metabolite of Abacavir, primarily identified as a drug impurity. This compound may be of interest during the quality control and analytical assessment of Abacavir formulations. Its presence can provide insights into the stability and degradation pathways of the active pharmaceutical ingredient in biological and pharmaceutical research. -
Drug Impurity
Candesartan impurity 18 is a known impurity associated with the angiotensin II receptor antagonist, Candesartan. This compound serves as a reference standard for quality control and analytical studies in pharmaceutical development. It is essential for ensuring the integrity and compliance of Candesartan formulations in research and development settings. -
Drug Impurity
Simvastatin impurity 3 is a chemical impurity associated with the cholesterol-lowering agent Simvastatin. This compound is primarily utilized in drug formulation analysis to identify and quantify impurities in the synthesis of Simvastatin. Its presence is critical for ensuring the quality and safety of pharmaceutical products, making it an essential reagent for regulatory compliance and formulation development in the pharmaceutical industry. -
Drug Impurity
Trazodone impurity 19 is a known impurity associated with the antidepressant trazodone. It plays a significant role in quality control and assessment within pharmaceutical development, helping to ensure the purity and safety of drug formulations. This compound can be utilized in research applications to study trazodone's stability and degradation pathways, facilitating the development of more effective antidepressant therapies. -
Drug Impurity
Azilsartan impurity 20, also known as Azilsartan amidoxime, is a chemical impurity associated with the pharmaceutical compound Azilsartan. Its presence is important for ensuring the quality and safety of pharmaceutical formulations. This compound is primarily utilized in quality control and analytical research to assess the purity of Azilsartan and evaluate its synthesis processes. -
Drug Impurity
Sofosbuvir impurity 5 is a known impurity of the antiviral drug Sofosbuvir, which targets the RNA-dependent RNA polymerase of hepatitis C virus. This compound is essential for analytical research and quality control in the development of Sofosbuvir formulations. Its characterization and quantification are important for ensuring the purity and efficacy of the final pharmaceutical product. -
Drug Impurity
Irbesartan impurity 1 is a byproduct associated with the synthesis of Irbesartan, an angiotensin II receptor blocker. This chemical is essential for quality control and method validation in pharmaceutical research and development. Its characterization is crucial for ensuring the safety and efficacy of the final drug product, supporting regulatory compliance and analytical assessments. -
Drug Impurity
Amlodipine impurity 3 is a specific impurity associated with the calcium channel blocker Amlodipine. This compound is significant for drug quality assessments and regulatory compliance in pharmaceutical research. It is utilized in the development and validation of analytical methods for the quantification and characterization of impurities in drug formulations. -
Drug Impurity
Aripiprazole impurity 26, also known as N-(Chloroacetyl)-m-anisidide, is identified as a drug impurity associated with Aripiprazole. This compound is of interest for analytical chemistry and quality control in pharmaceutical research, assisting in the characterization and validation of drug substances. Its presence may be relevant in studying the purity and stability of Aripiprazole formulations. -
Drug Impurity
Candesartan impurity 10 is a structural impurity related to Candesartan, an angiotensin II receptor blocker. This compound is primarily utilized for quality control and analytical purposes in the development and production of Candesartan pharmaceuticals. Its identification and quantification are essential for ensuring the purity and regulatory compliance of Candesartan formulations in drug development. -
Drug Impurity
Salmeterol impurity 4, also known as Salmeterol impurity G, is a known impurity associated with the beta-2 adrenergic agonist Salmeterol. Its presence is important for quality control and analytical studies of Salmeterol formulations. Researchers can utilize this impurity to assess the purity and stability of Salmeterol during drug development processes. -
Drug Impurity
Telmisartan impurity 6 is a synthetic byproduct of Telmisartan, functioning primarily as a drug impurity. It is important for quality control and analytical studies in pharmacological research, assisting in the assessment of pharmaceutical formulations and safety profiles. This impurity is useful in understanding the stability and degradation pathways of Telmisartan, contributing to the overall evaluation of drug quality and efficacy. -
Drug Impurity
Ketoprofen Impurity 7 is a chemical impurity associated with the nonsteroidal anti-inflammatory drug, Ketoprofen. It serves as an important reference standard for method development and validation in pharmaceutical research and quality control. Investigating this impurity facilitates a better understanding of Ketoprofen’s chemical profile, stability, and potential effects on drug performance and safety. -
Heroin Impurity
ATM4 4-Acetoxy analog is identified as an impurity associated with the synthesis of heroin. This compound plays a notable role in chemical research related to opioid synthesis and quality control. Its characterization is crucial for understanding the intricacies of heroin production and ensuring regulatory compliance within drug development processes. -
Amphetamines Impurity
1,2-Dibromo-4,5-methylenedioxybenzene is an impurity associated with the synthesis of amphetamines. This compound is relevant for analytical research and quality control in the production of amphetamine derivatives. Its presence may influence the pharmacological properties of synthesized compounds, making it an important target for study in chemical research focused on amphetamine-related substances. -
Impurity of Valsartan
D-Valsartan is an impurity of Valsartan, which functions primarily as an angiotensin II receptor antagonist. It plays a critical role in the characterization of Valsartan and is essential for purity assessments during pharmaceutical development. This compound serves as a reference in research applications aimed at understanding the pharmacological profile and safety of angiotensin II receptor modulators. -
Process-related Impurity
NW-1689 is a process-related impurity of safinamide mesilate (SAFM) and exhibits similar chemical characteristics. It functions primarily as a reversible inhibitor of monoamine oxidase-B (MAO-B) and shares pharmacological properties with SAFM, contributing to reduced dopamine degradation and glutamate release. This compound is relevant for research focused on Parkinson's disease, supporting investigations into neuroprotective mechanisms and potential therapeutic effects.
